Fluoxetine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Fluoxetine: From Depression to Schizoid Personality Disorder
One-Sentence Summary
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) widely known for the treatment of depression and related mood/anxiety disorders. The TxGNN model predicts it may be effective for Schizoid Personality Disorder, but this direction is currently supported only by 3 tangential publications and no registered clinical trials, none of which directly studied the disorder as a primary treatment target.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the Evidence Pack (no marketing licences or indication text on file — see UK Market Information below) |
| Predicted New Indication | Schizoid Personality Disorder |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack (Data Gap DG002). Based on general pharmacological knowledge, fluoxetine belongs to the SSRI class, acting by inhibiting neuronal reuptake of serotonin (5-HT) to increase synaptic serotonergic tone. Its efficacy in depressive and anxiety-spectrum conditions is well established in clinical practice, though the Evidence Pack itself contains no formal original-indication record or UK marketing authorisation for this compound.
The predicted link to schizoid personality disorder is mechanistically weak. The rationale supplied with this candidate notes explicitly that there is no direct pharmacological argument connecting SSRIs to the core features of schizoid personality disorder (affective flatness, social withdrawal, reduced capacity for interpersonal attachment). SSRIs are only known to relieve comorbid depressive or anxiety symptoms that may co-occur with the disorder, rather than the disorder’s core psychopathology itself.
Consistent with this, none of the three supporting publications studied fluoxetine (or SSRIs generally) as a primary treatment for schizoid personality disorder — they address personality traits in body dysmorphic disorder, a general review of pharmacotherapy in cluster A personality disorders, and predictors of depression outcome. The association identified by TxGNN should therefore be regarded as an indirect, network-level signal rather than a mechanistically grounded hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29955451 | 2016 | Review | The Mental Health Clinician | Reviews pharmacological treatment options for cluster A personality disorders (paranoid, schizoid, schizotypal), noting patients tend to be isolative and that evidence for any specific drug class, including SSRIs, is limited. |
| 16390895 | 2006 | Cohort | The American Journal of Psychiatry | Six-month outcome study of depressed patients under treatment, examining predictors of illness course; personality pathology was assessed but was not the primary treatment target. |
| 10929788 | 2000 | Cohort | Comprehensive Psychiatry | Assessed personality traits and disorders (including schizoid traits) in patients with body dysmorphic disorder; some subjects had received fluvoxamine, not fluoxetine, for the primary disorder. |
UK Market Information
Fluoxetine is recorded as not marketed in this Evidence Pack, with 0 marketing authorisations on file. No product name, dosage form, or approved indication text is available to report.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: key warnings, contraindications, and drug interaction data were flagged as a Blocking data gap (DG001 — TFDA/MHRA product label warnings and contraindications) and could not be retrieved for this evaluation.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence Level L4 reflects mechanism/preclinical-tier support at best — there are no clinical trials and only three publications, none of which studied fluoxetine as a treatment for schizoid personality disorder specifically. The repurposing rationale itself concludes the mechanistic link is indirect, relying only on relief of comorbid mood/anxiety symptoms rather than the disorder’s core features.
To proceed, the following is needed:
- Fluoxetine’s mechanism of action data (DG002) to properly assess mechanistic plausibility
- MHRA/SmPC-sourced warnings and contraindications (DG001, currently Blocking) before any safety evaluation can begin
- Primary studies or trials assessing SSRI treatment specifically in schizoid personality disorder populations, rather than in comorbid or unrelated conditions
- Confirmation of UK marketing status, given the Evidence Pack currently shows no licences for this product
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.